FEASIBILITY OF CRISPR-CAS9-BASED IN VITRO DRUG TARGET INDENTIFICATION FOR PERSONALIZED PROSTATE CANCER MEDICINE

$134,569FY2016Department of DefenseDOD

Tampereen Yliopisto

Investigators